Home » Topics » BioWorld Science

BioWorld Science
RSS

Novel CAR.CD30 T-cell therapy shows potential in vivo activity

Nov. 4, 2019

Serum endocan as biomarker to predict postablation recurrence of HCC

Nov. 4, 2019

CTLA-4 plus PD-1 equals more than the sum of its parts

Nov. 4, 2019

Millennium Pharmaceuticals initiates phase I/II study of TAK-981 plus rituximab in NHL

Oct. 31, 2019

First biologic treatment approved for children with lupus in Europe

Oct. 31, 2019

ACADIA Pharmaceuticals initiates phase III LAVENDER study of trofinetide in Rett syndrome

Oct. 31, 2019

New JAK-2 inhibitors identified at East China University of Science and Technology

Oct. 31, 2019

GlaxoSmithKline Biologicals presents new Toll-like receptor 7/8 agonists

Oct. 31, 2019

FDA approves Vumerity for the treatment of multiple sclerosis

Oct. 31, 2019

First patient dosed in phase II study of novel hepcidin mimetic PTG-300

Oct. 31, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...